Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TTBK1 | Q5TCY1 | 7/20 | 0.41 |
| ▸ | TTBK2 | Q6IQ55 | 7/20 | 0.41 |
| ▸ | LRRK2 | Q5S007 | 9/20 | 0.37 |
| ▸ | CSF1R | P07333 | 2/20 | 0.35 |
| ▸ | GLA | P06280 | 1/20 | 0.33 |
| ▸ | RET | P07949 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9918523 | 0.81 | MAPT (0.41) | TTBK1TTBK2CSF1R | |
| SCHEMBL9918518 | 0.81 | LRRK2 (0.37) | LRRK2 | |
| SCHEMBL9918517 | 0.78 | RET (0.35) | TTBK1TTBK2LRRK2RET | |
| SCHEMBL9921765 | 0.74 | TTBK1 (0.40) | TTBK1TTBK2LRRK2CSF1R | |
| SCHEMBL9918526 | 0.73 | LRRK2 (0.43) | LRRK2 | |
| SCHEMBL9918542 | 0.73 | TTBK1 (0.37) | TTBK1TTBK2LRRK2CSF1R | |
| SCHEMBL12833307 | 0.72 | LRRK2 (0.43) | TTBK1TTBK2LRRK2CSF1RRET | |
| SCHEMBL9918545 | 0.71 | CSF1R (0.46) | LRRK2CSF1RGLA | |
| SCHEMBL12832928 | 0.71 | LRRK2 (0.45) | LRRK2 | |
| SCHEMBL9918522 | 0.71 | CSF1R (0.38) | TTBK1TTBK2CSF1R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120149662-A1 | Heterocyclic Compounds as Janus Kinase Inhibitors | BIOCRYST PHARMACEUTICALS, INC. (US) | 2012-06-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120149662-A1 | Heterocyclic Compounds as Janus Kinase Inhibitors | JAK2, JAK1, JAK3 | TTBK1 597/4885TTBK2 854/4885LRRK2 1567/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.